Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 6:17:85-101.
doi: 10.2147/OPTH.S389406. eCollection 2023.

Systematic Literature Review of Clinical, Economic, and Humanistic Outcomes Following Minimally Invasive Glaucoma Surgery or Selective Laser Trabeculoplasty for the Treatment of Open-Angle Glaucoma with or Without Cataract Extraction

Louis Cantor  1 , Dan Lindfield  2 , Federico Ghinelli  3 , Anna W Świder  3 , Francesca Torelli  3 , Carolyn Steeds  3 , Jaime E Dickerson Jr  4   5 , Dan Q Nguyen  6
Affiliations
Review

Systematic Literature Review of Clinical, Economic, and Humanistic Outcomes Following Minimally Invasive Glaucoma Surgery or Selective Laser Trabeculoplasty for the Treatment of Open-Angle Glaucoma with or Without Cataract Extraction

Louis Cantor et al. Clin Ophthalmol. .

Abstract

Introduction: Selective laser trabeculoplasty (SLT) and minimally invasive glaucoma surgery (MIGS) are increasingly used options for mild-to-moderate open-angle glaucoma (OAG) care. While most MIGS devices are indicated for use in combination with cataract surgery only, with phacoemulsification playing a role in lowering IOP, newer technologies can also be used as standalone glaucoma surgery.

Methods: This systematic literature review (SLR) aimed to assess the clinical, economic, and humanistic outcomes of MIGS and SLT for the treatment of OAG and was conducted according to PRISMA guidelines. Studies that assessed MIGS or SLT in at least one treatment arm versus any other glaucoma treatment in adults with mild-to-moderate OAG were included. Clinical, humanistic (health-related quality of life [HRQoL] and patient burden), and economic data were extracted, and the methodological quality of included studies was evaluated.

Results: A total of 2720 articles were screened, and 81 publications were included. Fifty-eight reported clinical outcomes. The majority assessed iStent or iStent inject (n=41), followed by OMNI (n=9), gonioscopy-assisted transluminal trabeculotomy (GATT) or the Kahook Dual Blade (KDB) (n=7), Hydrus (n=6), SLT (n=5), Xen Gel Stent (n=2), PreserFlo (n=1), and iTrack (n=1). IOP reduction was observed across prospective studies, varying from -31% to -13.7% at month 6 and from -39% to -11.4% at year 1 versus baseline. Most adverse events were transient and non-serious. Limited humanistic and economic data were identified.

Conclusion: Given their established efficacy and safety, there is a rationale for wider use of MIGS in mild-to-moderate OAG. Of the MIGS devices, iStent and OMNI have the largest clinical evidence base supporting their sustained effectiveness.

Keywords: IOP; MIGS; OMNI; SLT; iStent; intraocular pressure.

PubMed Disclaimer

Conflict of interest statement

Louis Cantor, Dan Lindfield, and Dan Nguyen have received honoraria from Sight Sciences. Louis Cantor also reports consulting fees from Zeiss Meditec, Santen, Elios, and Avellino over the past two years and grants from Allergan, outside the submitted work. Francesca Torelli, Carolyn Steeds, Anna W Świder, and Federico Ghinelli are affiliated with Valid Insight, which is a consulting firm commissioned by Sight Sciences that funded this systematic literature review. Jaime E Dickerson, Jr is an active employee at Sight Sciences. Dan Nguyen has received consulting fees from AbbVie/Allergan, Alcon, Vision Engineering, and Elios. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
PRISMA flow diagram.
See this image and copyright information in PMC

References

    1. Allison K, Patel D, Alabi O. Epidemiology of Glaucoma: the Past, Present, and Predictions for the Future. Cureus. 2020;12(11):e11686. doi: 10.7759/cureus.11686 - DOI - PMC - PubMed
    1. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130(4):429–440. doi: 10.1016/S0002-9394(00)00538-9 - DOI - PubMed
    1. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901–1911. doi: 10.1001/jama.2014.3192 - DOI - PMC - PubMed
    1. Diagnosis And Management. National Institute for Health and Care Excellence. Glaucoma: Diagnosis And Management; 2022. - PubMed
    1. Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019;393(10180):1505–1516. doi: 10.1016/S0140-6736(18)32213-X - DOI - PMC - PubMed